These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2738947)

  • 1. Antibacterial activity of norfloxacin against bacterial isolates from the urinary tract.
    Qadri SM; Johnson S
    J Natl Med Assoc; 1989 Apr; 81(4):382-5. PubMed ID: 2738947
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibacterial activity of norfloxacin against 1700 relatively resistant clinical isolates.
    Qadri SM; Lee G; Brodie L
    Drugs Exp Clin Res; 1989; 15(8):349-53. PubMed ID: 2598776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro activity of norfloxacin against gram-positive and gram-negative organisms from recent clinical isolates].
    Mancini C; Brenciaglia MI; Ghezzi MC; Giordano A; Nazzari C; Cipriani P
    Boll Ist Sieroter Milan; 1985; 64(4):289-93. PubMed ID: 3935135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative in vitro activity of norfloxacin and four other chemotherapeutics against urinary gram-negative isolates.
    Esposito S; Galante D; Pennucci C; Barba D; Limauro D; Scioli C
    Chemioterapia; 1984 Jun; 3(3):196-9. PubMed ID: 6241506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activity of ciprofloxacin and five other quinoline derivatives against gram-negative isolates.
    Galante D; Pennucci C; Esposito S; Barba D
    Drugs Exp Clin Res; 1985; 11(5):331-4. PubMed ID: 2941260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Norfloxacin, a fluoroquinolone antibacterial agent. Classification, mechanism of action, and in vitro activity.
    Goldstein EJ
    Am J Med; 1987 Jun; 82(6B):3-17. PubMed ID: 3111257
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Susceptibility in vitro to certain quinolines of gram-negative bacteria and gram-positive cocci causing urinary tract infections].
    Mróz E; Jankowski S; Bartelmus J; Grzybek-Hryncewicz K; Ruczkowska J; Starek J; Boratyńska M
    Med Dosw Mikrobiol; 1993; 45(1):115-8. PubMed ID: 8231429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ofloxacin: antibacterial activity, induction of resistance and killing curves.
    Husson MO; Izard D; Bryskier A; Leclerc H
    Chemioterapia; 1985 Aug; 4(4):278-83. PubMed ID: 3863716
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
    Croize J; Le Noc P; Bryskier A; Robert J
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Laboratory assessment of lomefloxacin (SC-47111) in comparison with norfloxacin.
    Edwards R; Kanematsu M; Greenwood D
    J Antimicrob Chemother; 1988 Dec; 22(6):885-90. PubMed ID: 3243736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Urinary infection. I. Comparative in vitro activities of several antibiotic drugs against Gram-negative bacteria].
    Giachino F; Allocco A; Tuninetti L; Tullio V; Cuffini AM; Carlone NA
    G Batteriol Virol Immunol; 1992 Jan-1993 Dec; 85(1-12):55-67. PubMed ID: 7498617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the in vitro susceptibility of rifaximin versus norfloxacin against multidrug resistant bacteria in a hospital setting. A proof-of-concept study for use in advanced cirrhosis.
    Ramos JM; Vidal I; Bellot P; Gómez-Hurtado I; Zapater P; Such J
    Gut; 2016 Jan; 65(1):182-3. PubMed ID: 25832107
    [No Abstract]   [Full Text] [Related]  

  • 13. [In vitro fluoroquinolone resistance in ocular bacterial isolates].
    Sun XG; Wang ZQ; Li R; Chen L; Jin XY; Luo SY
    Zhonghua Yan Ke Za Zhi; 2003 Mar; 39(3):163-6. PubMed ID: 12880574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Norfloxacin: a broad-spectrum quinolone for superficial eye infections].
    Grosset J
    Pathol Biol (Paris); 1990 Sep; 38(7):735-41. PubMed ID: 2235090
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The sensitivity of gram-negative and gram-positive bacteria to ofloxacin.
    Speciale A; Stefani S; Caccamo F; Nicolosi VM; Nicoletti G
    Chemioterapia; 1987 Feb; 6(1):17-22. PubMed ID: 3470153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effect of norfloxacin in infections of the urinary and intestinal tracts: combined effects with aminoglucosides and with tetracycline and chloramphenicol].
    Mascellino MT; Lorenzi A; Bonanni M; Iegri F
    G Ital Chemioter; 1985; 32(2):497-500. PubMed ID: 3833594
    [No Abstract]   [Full Text] [Related]  

  • 17. [In vitro comparative activity of norfloxacin in the comparison of pathogenic bacteria of the urinary tract].
    Carlone NA; Cuffini AM; Tullio V; Savoia D; Cavallo GP
    G Batteriol Virol Immunol; 1986; 79(1-6):85-97. PubMed ID: 3479370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the in vitro activity of norfloxacin and other drugs on amoxicillin-resistant uropathogenic isolates.
    Piccolomini R; Allocati N; Catamo G
    Chemioterapia; 1984 Jun; 3(3):167-72. PubMed ID: 6241505
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 1-Chloropiperazinic derivative (ER 311) of norfloxacin: antibacterial activity in vitro and pharmacokinetic properties in mice.
    Dubini F; Balsari A; Stradi R; Riviera L
    Chemioterapia; 1987 Jun; 6(2 Suppl):178-80. PubMed ID: 3509385
    [No Abstract]   [Full Text] [Related]  

  • 20. Bacterial profile and drug susceptibility pattern of urinary tract infection in pregnant women at Tikur Anbessa Specialized Hospital Addis Ababa, Ethiopia.
    Assefa A; Asrat D; Woldeamanuel Y; G/Hiwot Y; Abdella A; Melesse T
    Ethiop Med J; 2008 Jul; 46(3):227-35. PubMed ID: 19271386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.